The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
Open Access
- 19 December 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 10 (3) , 797-805
Abstract
The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3‐mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact of FLT3 mutation clearance and the achievement of composite complete remission (CRc) and complete remission/complete remission with partial hematologic recovery (CR/CRh) on overall survival (OS) in patients with FLT3mut+ R/R AML treated with single‐agent gilteritinib in a phase 1/2 trial were evaluated. Using next‐generation sequencing, a FLT3‐ITD variant allele frequency of ≤10−4 was used to define FLT3‐ITD clearance in patients with no morphologic leukemia (ie, CRc). A total of 108 patients with FLT3‐ITD‐positive (FLT3‐ITD+) R/R AML were analyzed; 95 of these patients had received ≥80‐mg/day gilteritinib. Ten of the 95 patients had FLT3‐ITD clearance; eight of these 10 patients achieved CRc and were considered negative for measurable residual disease. There was a trend toward longer OS in patients who attained CRc with FLT3‐ITD clearance (131.4 weeks) versus those who achieved CRc and did not have FLT3‐ITD clearance (n = 41; 43.3 weeks; HR = 0.416; p = 0.066). Among patients treated with ≥80‐mg/day gilteritinib who achieved CR/CRh (n = 24), seven had FLT3‐ITD clearance. Among patients who received 120‐mg/day gilteritinib, those who achieved CR/CRh had a longer median OS (70.6 weeks) and higher 52‐week survival probability (66.7%) than patients who did not achieve CR/CRh (n = 71; median OS, 41.7 weeks; 52‐week survival probability, 20.2%). Overall, these data suggest that gilteritinib can induce deep molecular responses in patients with FLT3‐ITD+ R/R AML, and in the setting of CRc or CR/CRh, these responses may be associated with prolonged survival.Keywords
This publication has 27 references indexed in Scilit:
- Minimal residual disease in acute myelogenous leukemiaInternational Journal of Laboratory Hematology, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Preclinical studies of gilteritinib, a next-generation FLT3 inhibitorBlood, 2017
- A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype IdentifiesFLT3-Mutated Clones in Acute Myeloid LeukemiaClinical Cancer Research, 2015
- Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant diseaseLeukemia, 2013
- Identification of emerging FLT3 ITD‐positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosminBritish Journal of Haematology, 2013
- Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AMLBlood, 2012
- Molecular analysis of differentFLT3-ITD mutations in acute myeloid leukemiaLeukemia & Lymphoma, 2012
- Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemiaHaematologica, 2009
- FLT3: the root of the problemBlood, 2006